ESMO 2022 Conference Coverage
Playback speed
10 seconds
ESMO 2022 on Outcomes of Real World Patients With Advanced NSCLC and High PD-L1 Expression Receiving 1L Immune Checkpoint Inhibitor Therapy
By
ESMO 2022 Conference Coverage
FEATURING
Melinda Hsu
By
ESMO 2022 Conference Coverage
FEATURING
Melinda Hsu
96 views
September 27, 2022
Comments 0
Login to view comments.
Click here to Login
Lung